“Although they may slow the spread, and we need more resources to do that, longer term the solutions must be either immunotherapy, which is putting serum into infected patients, but most importantly of course in the longer term, a vaccine.”
He said that phase one human trials of potential vaccines, in the United States, United Kingdom, and Mali, have so far presented no safety concerns. Volunteers in Oxford were given a trial vaccine last month.
“So then if that continues to be good news, then the question is an international agency and regulatory authority one – it is how can we speed up the process of getting this trial vaccine, first of all manufactured on a scale, and that’s a challenge, real challenge, for the companies, and then deploy it as quickly as possible.”